Although TACR3 antagonism show promise for cancer treatment, particularly in tumor-associated disorders, these adverse effects emphasize the importance of ongoing hepatic monitoring and further evaluation to ensure the safe application in conjunction with other means of cancer therapies. The gene discussed is TACR3; the disease is cancer.